Representative Gilbert Ray Cisneros, Jr. (D-California) recently sold shares of Laboratory Co. of America Holdings (NYSE:LH). In a filing disclosed on April 07th, the Representative disclosed that they had sold between $1,001 and $15,000 in Laboratory Co. of America stock on March 31st. The trade occurred in the Representative's "150 MAIN STREET TRUST > BANK OF AMERICA" account.
Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):
- Purchased $15,001 - $50,000 in shares of PTC NASDAQ: PTC on 4/1/2025.
- Sold $1,001 - $15,000 in shares of W. R. Berkley NYSE: WRB on 4/1/2025.
- Sold $15,001 - $50,000 in shares of GoDaddy NYSE: GDDY on 4/1/2025.
- Purchased $1,001 - $15,000 in shares of Ford Motor NYSE: F on 3/31/2025.
- Sold $15,001 - $50,000 in shares of Microsoft NASDAQ: MSFT on 3/31/2025.
- Sold $15,001 - $50,000 in shares of Pfizer NYSE: PFE on 3/31/2025.
- Purchased $1,001 - $15,000 in shares of Boeing NYSE: BA on 3/31/2025.
- Sold $1,001 - $15,000 in shares of Hologic NASDAQ: HOLX on 3/31/2025.
- Sold $15,001 - $50,000 in shares of Merck & Co., Inc. NYSE: MRK on 3/31/2025.
- Sold $1,001 - $15,000 in shares of Tesla NASDAQ: TSLA on 3/31/2025.
Laboratory Co. of America Stock Performance
LH traded up $2.85 during trading on Friday, hitting $221.46. The stock had a trading volume of 1,031,685 shares, compared to its average volume of 637,954. The company has a current ratio of 1.44, a quick ratio of 1.30 and a debt-to-equity ratio of 0.67. Laboratory Co. of America Holdings has a 12 month low of $191.97 and a 12 month high of $258.59. The company has a 50 day simple moving average of $240.04 and a 200-day simple moving average of $234.91. The firm has a market cap of $18.53 billion, a PE ratio of 25.11, a P/E/G ratio of 1.71 and a beta of 0.99.
Laboratory Co. of America (NYSE:LH - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The medical research company reported $3.45 earnings per share for the quarter, topping the consensus estimate of $3.40 by $0.05. Laboratory Co. of America had a return on equity of 15.29% and a net margin of 5.73%. Analysts expect that Laboratory Co. of America Holdings will post 16.01 EPS for the current year.
Laboratory Co. of America Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Wednesday, June 11th. Investors of record on Thursday, May 29th will be paid a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a yield of 1.30%. Laboratory Co. of America's payout ratio is presently 32.65%.
Insider Transactions at Laboratory Co. of America
In related news, CEO Adam H. Schechter sold 6,121 shares of the firm's stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $244.62, for a total value of $1,497,319.02. Following the completion of the sale, the chief executive officer now owns 86,445 shares of the company's stock, valued at $21,146,175.90. This trade represents a 6.61 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CMO Amy B. Summy sold 226 shares of the business's stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $250.40, for a total transaction of $56,590.40. Following the completion of the transaction, the chief marketing officer now owns 4,544 shares of the company's stock, valued at $1,137,817.60. This trade represents a 4.74 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 14,258 shares of company stock worth $3,518,177. Insiders own 0.85% of the company's stock.
Analysts Set New Price Targets
Several equities research analysts have recently issued reports on LH shares. Truist Financial lowered their price objective on shares of Laboratory Co. of America from $285.00 to $274.00 and set a "buy" rating on the stock in a research note on Friday. UBS Group decreased their price target on shares of Laboratory Co. of America from $293.00 to $286.00 and set a "buy" rating on the stock in a research report on Tuesday, January 28th. Redburn Atlantic started coverage on shares of Laboratory Co. of America in a research report on Wednesday, April 2nd. They set a "buy" rating and a $276.00 price objective for the company. Evercore ISI upgraded shares of Laboratory Co. of America from an "in-line" rating to an "outperform" rating and increased their target price for the company from $260.00 to $265.00 in a research note on Tuesday, January 7th. Finally, Barclays lowered their price target on Laboratory Co. of America from $260.00 to $240.00 and set an "equal weight" rating on the stock in a research note on Thursday. Three analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Laboratory Co. of America presently has a consensus rating of "Moderate Buy" and an average target price of $268.77.
View Our Latest Stock Analysis on LH
Institutional Investors Weigh In On Laboratory Co. of America
Hedge funds have recently made changes to their positions in the company. WealthBridge Investment Counsel Inc. grew its stake in Laboratory Co. of America by 0.5% during the first quarter. WealthBridge Investment Counsel Inc. now owns 34,201 shares of the medical research company's stock worth $7,960,000 after buying an additional 175 shares during the last quarter. Procyon Advisors LLC bought a new stake in Laboratory Co. of America during the 1st quarter worth approximately $204,000. Contravisory Investment Management Inc. acquired a new stake in Laboratory Co. of America during the 1st quarter valued at $283,000. Merit Financial Group LLC increased its holdings in Laboratory Co. of America by 23.0% during the 1st quarter. Merit Financial Group LLC now owns 3,414 shares of the medical research company's stock valued at $795,000 after purchasing an additional 639 shares in the last quarter. Finally, NBC Securities Inc. bought a new position in Laboratory Co. of America in the 1st quarter valued at $130,000. Institutional investors and hedge funds own 95.94% of the company's stock.
About Representative Cisneros
Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California's 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.
Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California's 31st Congressional District. He declared candidacy for the 2026 election.
Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor's degree in political science from George Washington University in 1994, a master's in business administration from Regis University in 2002, and a master's degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.
About Laboratory Co. of America
(
Get Free Report)
Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.
Featured Stories
Before you consider Laboratory Co. of America, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Laboratory Co. of America wasn't on the list.
While Laboratory Co. of America currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
